Tin tức & Cập nhật

Among women receiving immunosuppression treatment with mammalian target of rapamycin inhibitors (mTORi), the incidence of ovarian cyst appears to be a common adverse event, according to the results of a systematic review and meta-analysis.

Extending treatment with letrozole for 5 years improves disease-free survival (DFS) rates in postmenopausal women with early-stage breast cancer who have already received tamoxifen for 2–3 years, according to the GIM4* trial.

Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.

Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.

Intravenous dosing regimens of vedolizumab appear to favourably alter outcomes in patients with fistulizing Crohn’s disease, according to data from the phase IV ENTERPRISE trial.

A large international database study has shown that children and adolescents with cancer have an elevated risk of severe or critical disease if infected with COVID-19. Furthermore, about half the patients receiving cancer therapy experienced modifications to their treatment regimens. 

Varenicline alone is an adequate therapy for smoking cessation in heavy-drinking smokers, but combining it with naltrexone may provide benefits in terms of drinking outcomes, particularly during the 12-week period of active medication treatment, suggests a study.